Study:
High Risk B-Precursor Acute Lymphoblastic Leukemia
Rationale:
Drugs used in chemotherapy, such as dexamethasone, prednisone, methotrexate, and
leucovorin calcium, work in different ways to stop cancer cells from dividing so they stop
growing or die. Giving more than one drug may kill more cancer cells. It is not yet known
which combination chemotherapy regimen is more effective in treating acute lymphoblastic
leukemia.
Purpose:
This randomized phase III trial is studying dexamethasone to see how well it works
compared to prednisone during induction therapy. This trial is also studying methotrexate
and leucovorin calcium to see how well they work compared to methotrexate alone during
maintenance therapy in treating patients with newly diagnosed acute lymphoblastic leukemia.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Leukemia |
Drug: cyclophosphamide
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: leucovorin calcium
Drug: mercaptopurine
Drug: methotrexate
Drug: pegaspargase
Drug: prednisone
Drug: thioguanine
Drug: vincristine sulfate
Radiation: radiation therapy |
Phase 3 |
Verified by
Children`s Oncology Group
January, 2011
Sponsored by: Children`s Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00075725
Study Type: Interventional
Study Design: Allocation: Randomized, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Eric C. Larsen, MD., Study Chair